Phylogenetic Analysis of a Newcastle Disease Virus Strain Isolated from Domestic Poultry and Its Potential for Vaccine Development in the Republic of Kazakhstan
Background/Objectives: Despite the availability of Newcastle disease (ND) vaccines, outbreaks have continued to occur for more than six decades, with significant economic consequences for the global poultry industry. The variability of the Newcastle disease virus requires constant monitoring, detect...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/5/440 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background/Objectives: Despite the availability of Newcastle disease (ND) vaccines, outbreaks have continued to occur for more than six decades, with significant economic consequences for the global poultry industry. The variability of the Newcastle disease virus requires constant monitoring, detection of new cases, and studies of the origin of the pathogen. The aim of this study was to develop an inactivated ND vaccine using a topical strain with different adjuvants and to compare them for stability, harmlessness, immunogenicity, and efficacy. Methods: A phylogenetic study of the F-gene of the ND strain isolated in Kazakhstan was conducted. The strain, which was selected to create a vaccine for the prevention of the disease, was revealed to belong to genotype VII class II and uploaded to GenBank (NCBI). Two different adjuvants, Montanide ISA 70 VG and Montanide ISA 78 VG, were used to create the vaccine. Birds were vaccinated intramuscularly. Results: Evaluations of antibody titers in the vaccinated groups during the experiment showed that the vaccines induced adequate levels of antibodies to provide protection against the virulent virus. High antibody titers were observed in the hemagglutination inhibition assay (HAI) in the vaccinated groups as early as 14 days post-vaccination in 100% of birds. The average antibody titer in both vaccinated groups exceeded 7 log2, sufficient to prevent clinical signs. None of the vaccinated birds exhibited clinical signs following control infection, whereas unvaccinated birds developed clinical manifestations within three days post-infection, leading to 100% mortality. Conclusions: The vaccine developed using the epizootic topical strain is stable, harmless, immunogenic, and effective when challenged with a virulent ND virus strain at a dose of 105 EID<sub>50/mL</sub>. |
|---|---|
| ISSN: | 2076-393X |